Literature DB >> 1684729

Up-regulation of opioid gene expression in spinal cord evoked by experimental nerve injuries and inflammation.

G Draisci1, K C Kajander, R Dubner, G J Bennett, M J Iadarola.   

Abstract

Opioid systems modulate nociceptive input at several levels of the CNS. At the spinal cord level neurons are present that express the genes coding for the precursors of the dynorphin and enkephalin opioid peptide families. We found that two conditions in rats, a chronic constriction injury to the sciatic nerve and peripheral inflammation, have a common consequence centrally: they evoke a large, rapid and sustained up-regulation of preprodynorphin mRNA. Both are also characterized by signs of hyperalgesia and increased primary afferent input. In contrast, there is little or no up-regulation of preprodynorphin mRNA following complete transection of the sciatic nerve or sciatic nerve crush. Furthermore, only minor alterations in the levels of preproenkephalin mRNA occur in any of the conditions, except for inflammation where the elevation is relatively small compared to that of preprodynorphin mRNA. These data imply that specific regulatory processes that include stimulation of opioid gene expression are strongly engaged in the spinal cord in certain types of peripheral nerve injuries and inflammation, but not in others. Marked and sustained up-regulation of the spinal cord dynorphin system distinguishes the chronic constriction injury model from other nerve injury models of pain.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1684729     DOI: 10.1016/0006-8993(91)91231-o

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  23 in total

1.  Chapter 9 The dorsal horn and hyperalgesia.

Authors:  Karin N Westlund
Journal:  Handb Clin Neurol       Date:  2006

2.  Increased release of serotonin in the spinal cord during low, but not high, frequency transcutaneous electric nerve stimulation in rats with joint inflammation.

Authors:  Kathleen A Sluka; Tammy L Lisi; Karin N Westlund
Journal:  Arch Phys Med Rehabil       Date:  2006-08       Impact factor: 3.966

3.  Dynorphin promotes abnormal pain and spinal opioid antinociceptive tolerance.

Authors:  T W Vanderah; L R Gardell; S E Burgess; M Ibrahim; A Dogrul; C M Zhong; E T Zhang; T P Malan; M H Ossipov; J Lai; F Porreca
Journal:  J Neurosci       Date:  2000-09-15       Impact factor: 6.167

4.  Spinal astrocytes produce and secrete dynorphin neuropeptides.

Authors:  Andrew Wahlert; Lydiane Funkelstein; Bethany Fitzsimmons; Tony Yaksh; Vivian Hook
Journal:  Neuropeptides       Date:  2013-01-03       Impact factor: 3.286

Review 5.  Importance of sex to pain and its amelioration; relevance of spinal estrogens and its membrane receptors.

Authors:  Alan R Gintzler; Nai-Jiang Liu
Journal:  Front Neuroendocrinol       Date:  2012-10-02       Impact factor: 8.606

6.  Antagonists of the kappa-opioid receptor enhance allodynia in rats and mice after sciatic nerve ligation.

Authors:  I Obara; J Mika; M K-H Schafer; B Przewlocka
Journal:  Br J Pharmacol       Date:  2003-09-01       Impact factor: 8.739

7.  Cyclic non-opioid dynorphin A analogues for the bradykinin receptors.

Authors:  Yeon Sun Lee; Michael Remesic; Cyf Ramos-Colon; Sara M Hall; Alexander Kuzmin; David Rankin; Frank Porreca; Josephine Lai; Victor J Hruby
Journal:  Bioorg Med Chem Lett       Date:  2016-10-06       Impact factor: 2.823

8.  Acute inflammation induces segmental, bilateral, supraspinally mediated opioid release in the rat spinal cord, as measured by mu-opioid receptor internalization.

Authors:  W Chen; J C G Marvizón
Journal:  Neuroscience       Date:  2009-03-17       Impact factor: 3.590

9.  Peripheral inflammation undermines the plasticity of the isolated spinal cord.

Authors:  Michelle A Hook; John R Huie; James W Grau
Journal:  Behav Neurosci       Date:  2008-02       Impact factor: 1.912

10.  Intrathecal CGRP8-37-induced bilateral increase in hindpaw withdrawal latency in rats with unilateral inflammation.

Authors:  L C Yu; P Hansson; G Brodda-Jansen; E Theodorsson; T Lundeberg
Journal:  Br J Pharmacol       Date:  1996-01       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.